Raza Hoda MD
@razahoda.bsky.social
Staff Pathologist at Cleveland Clinic & Assistant Professor of #Pathology Cleveland Clinic Lerner College of Medicine. Ask your healthcare provider if these tweets are right for you.
Neoadjuvant Chemotherapy in Breast Cancer:
The NSABP B-18 trial (1998) by Fisher et al. demonstrated that preoperative chemotherapy could shrink tumors, leading to more lumpectomies. #BreastCancer #Oncology #PathSky #MedSky #breastpath
pubmed.ncbi.nlm.nih.gov/9704717/
The NSABP B-18 trial (1998) by Fisher et al. demonstrated that preoperative chemotherapy could shrink tumors, leading to more lumpectomies. #BreastCancer #Oncology #PathSky #MedSky #breastpath
pubmed.ncbi.nlm.nih.gov/9704717/
Effect of preoperative chemotherapy on the outcome of women with operable breast cancer - PubMed
Preoperative chemotherapy is as effective as postoperative chemotherapy, permits more lumpectomies, is appropriate for the treatment of certain patients with stages I and II disease, and can be used t...
pubmed.ncbi.nlm.nih.gov
December 20, 2024 at 11:10 AM
Neoadjuvant Chemotherapy in Breast Cancer:
The NSABP B-18 trial (1998) by Fisher et al. demonstrated that preoperative chemotherapy could shrink tumors, leading to more lumpectomies. #BreastCancer #Oncology #PathSky #MedSky #breastpath
pubmed.ncbi.nlm.nih.gov/9704717/
The NSABP B-18 trial (1998) by Fisher et al. demonstrated that preoperative chemotherapy could shrink tumors, leading to more lumpectomies. #BreastCancer #Oncology #PathSky #MedSky #breastpath
pubmed.ncbi.nlm.nih.gov/9704717/
Gene Expression Profiling Leading to Molecular Subtypes of Breast Cancer:
Perou et al. (2000) published in Nature gave us the Luminal A/B, HER2-enriched, and Basal-like classifications.
#MolecularBiology #BreastCancer #BreastPathology #PathSky #BreastOncology
pubmed.ncbi.nlm.nih.gov/10963602/
Perou et al. (2000) published in Nature gave us the Luminal A/B, HER2-enriched, and Basal-like classifications.
#MolecularBiology #BreastCancer #BreastPathology #PathSky #BreastOncology
pubmed.ncbi.nlm.nih.gov/10963602/
Molecular portraits of human breast tumours - PubMed
Human breast tumours are diverse in their natural history and in their responsiveness to treatments. Variation in transcriptional programs accounts for much of the biological diversity of human cells ...
pubmed.ncbi.nlm.nih.gov
December 19, 2024 at 12:57 PM
Gene Expression Profiling Leading to Molecular Subtypes of Breast Cancer:
Perou et al. (2000) published in Nature gave us the Luminal A/B, HER2-enriched, and Basal-like classifications.
#MolecularBiology #BreastCancer #BreastPathology #PathSky #BreastOncology
pubmed.ncbi.nlm.nih.gov/10963602/
Perou et al. (2000) published in Nature gave us the Luminal A/B, HER2-enriched, and Basal-like classifications.
#MolecularBiology #BreastCancer #BreastPathology #PathSky #BreastOncology
pubmed.ncbi.nlm.nih.gov/10963602/
The Tamoxifen Trial.
Fisher et al. (1989) in the New England Journal of Medicine showed us the power of hormone therapy in ER+ breast cancer—a landmark study that revolutionized breast cancer treatment protocols.
pubmed.ncbi.nlm.nih.gov/2644532/
#BreastCancer #BreastOncology #Pathology #PathSky
Fisher et al. (1989) in the New England Journal of Medicine showed us the power of hormone therapy in ER+ breast cancer—a landmark study that revolutionized breast cancer treatment protocols.
pubmed.ncbi.nlm.nih.gov/2644532/
#BreastCancer #BreastOncology #Pathology #PathSky
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors - PubMed
We conducted a randomized, double-blind, placebo-controlled trial of postoperative therapy with tamoxifen (10 mg twice a day) in 2644 patients with breast cancer, histologically negative axillary node...
pubmed.ncbi.nlm.nih.gov
December 18, 2024 at 12:37 PM
The Tamoxifen Trial.
Fisher et al. (1989) in the New England Journal of Medicine showed us the power of hormone therapy in ER+ breast cancer—a landmark study that revolutionized breast cancer treatment protocols.
pubmed.ncbi.nlm.nih.gov/2644532/
#BreastCancer #BreastOncology #Pathology #PathSky
Fisher et al. (1989) in the New England Journal of Medicine showed us the power of hormone therapy in ER+ breast cancer—a landmark study that revolutionized breast cancer treatment protocols.
pubmed.ncbi.nlm.nih.gov/2644532/
#BreastCancer #BreastOncology #Pathology #PathSky
Understanding HER2 in Breast Cancer:
Slamon et al.'s 1987 study on HER2/neu amplification paved the way for targeted therapies like Herceptin. #HER2Positive #BreastCancer
pubmed.ncbi.nlm.nih.gov/3798106/
Slamon et al.'s 1987 study on HER2/neu amplification paved the way for targeted therapies like Herceptin. #HER2Positive #BreastCancer
pubmed.ncbi.nlm.nih.gov/3798106/
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene - PubMed
The HER-2/neu oncogene is a member of the erbB-like oncogene family, and is related to, but distinct from, the epidermal growth factor receptor. This gene has been shown to be amplified in human breas...
pubmed.ncbi.nlm.nih.gov
December 17, 2024 at 12:20 PM
Understanding HER2 in Breast Cancer:
Slamon et al.'s 1987 study on HER2/neu amplification paved the way for targeted therapies like Herceptin. #HER2Positive #BreastCancer
pubmed.ncbi.nlm.nih.gov/3798106/
Slamon et al.'s 1987 study on HER2/neu amplification paved the way for targeted therapies like Herceptin. #HER2Positive #BreastCancer
pubmed.ncbi.nlm.nih.gov/3798106/
Estrogen Receptor in Breast Carcinoma.
Remmele & Stegner's 1987 study revolutionized how we diagnose and treat breast carcinoma by identifying ER by immunohistochemistry. #BreastCancer #BreastPath
pubmed.ncbi.nlm.nih.gov/3303008/
Remmele & Stegner's 1987 study revolutionized how we diagnose and treat breast carcinoma by identifying ER by immunohistochemistry. #BreastCancer #BreastPath
pubmed.ncbi.nlm.nih.gov/3303008/
[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue] - PubMed
[Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]
pubmed.ncbi.nlm.nih.gov
December 16, 2024 at 12:25 PM
Estrogen Receptor in Breast Carcinoma.
Remmele & Stegner's 1987 study revolutionized how we diagnose and treat breast carcinoma by identifying ER by immunohistochemistry. #BreastCancer #BreastPath
pubmed.ncbi.nlm.nih.gov/3303008/
Remmele & Stegner's 1987 study revolutionized how we diagnose and treat breast carcinoma by identifying ER by immunohistochemistry. #BreastCancer #BreastPath
pubmed.ncbi.nlm.nih.gov/3303008/
I’ll try something new on Bluesky and post small summaries of landmark papers in breast cancer.
Discovering the BRCA1 Gene: A Game-Changer in Breast Cancer Genetics.
Miki et al. (1994) opened new avenues for understanding hereditary breast cancer. #BreastCancer
pubmed.ncbi.nlm.nih.gov/7545954/
Discovering the BRCA1 Gene: A Game-Changer in Breast Cancer Genetics.
Miki et al. (1994) opened new avenues for understanding hereditary breast cancer. #BreastCancer
pubmed.ncbi.nlm.nih.gov/7545954/
pubmed.ncbi.nlm.nih.gov
December 15, 2024 at 9:16 PM
I’ll try something new on Bluesky and post small summaries of landmark papers in breast cancer.
Discovering the BRCA1 Gene: A Game-Changer in Breast Cancer Genetics.
Miki et al. (1994) opened new avenues for understanding hereditary breast cancer. #BreastCancer
pubmed.ncbi.nlm.nih.gov/7545954/
Discovering the BRCA1 Gene: A Game-Changer in Breast Cancer Genetics.
Miki et al. (1994) opened new avenues for understanding hereditary breast cancer. #BreastCancer
pubmed.ncbi.nlm.nih.gov/7545954/